Polymorphisms in promoter region of FAS and FASL gene and risk of gastric cardiac adenocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 3, 2010, Pages 555-561

  Zhou, Rong Miao ^a   Wang, Na ^a   Chen, Zhi Feng ^a   Duan, Ya Nan ^a   Sun, Dong Lan ^a   Li, Yan ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

FAS; FASL; Gastric cardiac adenocarcinoma; Polymorphism; Susceptibility

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CANCER RISK; CARDIA CARCINOMA; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; CANCER INCIDENCE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CHINA; DIGESTIVE SYSTEM CANCER; FAS GENE; FASL GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; ONCOGENE; RISK REDUCTION; SMOKING; STOMACH ADENOCARCINOMA;

EID: 77649204679     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06116.x     Document Type: Article

References (46)

1. He YT, Hou J, Chen ZF et al. An analysis of gastric cardia cancer incidence in Cixian for 15 years. Chin. J. Public Health 2006 22 : 1434 1435.
2. Fielding JWL, Powell J, Allum WH. Cancer of the Stomach. London : The Macmillan Press, 1989.
3. Launoy G, Milan CH, Faivre J, Pienkowski P, Milan CI, Gignoux M. Alcohol, tobacco and oesophageal cancer: effects of the duration of consumption, mean intake and current and former consumption. Br. J. Cancer 1997 75 : 1389 1396.
4. Yokokawa Y, Ohta S, Hou J et al. Ecological study on the risks of esophageal cancer in Ci-Xian, China: the importance of nutritional status and the use of well water. Int. J. Cancer 1999 83 : 620 624.
5. Yang CS. Vitamin nutrition and gastroesophageal cancer. J. Nutr. 2000 130 : 338S 9S.
6. Cai L, Yu SZ, Zhang ZF. Helicobacter pylori infection and risk of gastric cancer in Changle County, Fujian Province, China. World J. Gastroenterol. 2000 6 : 374 376.
7. Matsha T, Erasmus R, Kafuko AB et al. Human papillomavirus associated with oesophageal cancer. J. Clin. Pathol. 2002 55 : 587 590.
8. Lavergne D, De Villiers EM. Papillomavirus in esophageal papillomas and carcinomas. Int. J. Cancer 1999 80 : 681 684.
9. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001 411 : 342 348.
10. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000 21 : 485 495.
11. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 1998 101 : 2579 2588.
12. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996 184 : 1075 1082.
13. Crnogorac-Jurcevic T, Efthimiou E, Capelli P et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001 20 : 7437 7446.
14. Gartas C, Tohmoa Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Upregulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 1998 58 : 2057 2062.
15. Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997 57 : 1007 1012.
16. Bennett MW, O'Connell J, O'Sullivan GC et al. The Fas counterattack in vivo: apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 1998 160 : 5669 5675.
17. Von Bernstorff W, Spanjaard RA, Chan AK et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999 125 : 73 84.
18. Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumorinfiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J. Cancer Res. Clin. Oncol. 2001 127 : 20 6.
19. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 1997 34 : 577 582.
20. Sibley K, Rollinson S, Allan JM et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003 63 : 4327 4330.
21. Wu J, Metz C, Xu X et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J. Immunol. 2003 170 : 132 138.
22. Lima L, Morais A, Lobo F, Calais-Da-Silva FM, Calais-Da-Silva FE, Medeiros R. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis. 2008 11 : 94 8.
23. Zhang B, Sun T, Xue L et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007 28 : 1067 1073.
24. Li C, Larson D, Zhang Z et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet. Genomics 2006 16 : 253 263.
25. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl Cancer Inst. 2004 96 : 1030 1036.
26. Qiu LX, Shi J, Yuan H et al. FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum. Genet. 2009 125 : 431 435.
27. Zhang Z, Xue H, Gong W et al. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 2009 30 : 487 493.
28. Zhang Z, Qiu L, Wang M, Tong N, Li J, Zhang Z. The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur. J. Hum. Genet. 2009 17 : 1294 1303.
29. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988 16 : 1215.
30. Zhang Z, Wang LE, Sturgis EM et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2006 12 : 5596 5602.
31. Yang M, Sun T, Wang L et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin. Cancer Res. 2008 14 : 3230 3236.
32. Crew KD, Gammon MD, Terry MB et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 2007 28 : 2548 2551.
33. Zhang H, Sun XF, Synnerstad I, Rosdahl I. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J. 2007 13 : 233 237.
34. Park SH, Choi JE, Kim EJ et al. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 2006 54 : 303 308.
35. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell. Immunol. 1999 192 : 48 53.
36. Bijl M, Horst G, Limburg PC, Kallenberg CG. Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur. J. Clin. Invest. 2001 31 : 550 553.
37. Wang M, Wu D, Tan M et al. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem. Genet. 2009 47 : 559 568.
38. Ivansson EL, Gustavsson IM, Magnusson JJ et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int. J. Cancer 2007 121 : 2451 2457.
39. Erdogan M, Karadeniz M, Berdeli A et al. Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J. Endocrinol. Invest. 2007 30 : 411 416.
40. Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res. 2007 27 : 991 994.
41. Yang S, Miao XP, Zhang XM et al. Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer. Zhonghua Yi Xue Za Zhi 2005 85 : 2132 2135.
42. Sun T, Zhou Y, Li H et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J. Exp. Med. 2005 202 : 967 974.
43. Zhang X, Miao X, Sun T et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J. Med. Genet. 2005 42 : 479 484.
44. Ter-Minassian M, Zhai R, Asomaning K et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 2008 29 : 2147 2152.
45. Kanemitsu S, Ihara K, Saifddin A et al. A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J. Rheumatol. 2002 29 : 1183 1188.
46. Wu J, Alizadeh BZ, Veen TV, Meijer JW, Mulder CJ, Pena AS. Association of FAS (TNFRSF6)-670 gene polymorphism with villous atrophy in coeliac disease. World J. Gastroenterol. 2004 10 : 717 720.